Prothena Corporation plc (PRTA) and VIVUS Inc. (NASDAQ:VVUS) Comparing side by side

As Biotechnology businesses, Prothena Corporation plc (NASDAQ:PRTA) and VIVUS Inc. (NASDAQ:VVUS), are affected by compare. This especially applies to their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Prothena Corporation plc 10 418.86 N/A -3.20 0.00
VIVUS Inc. 4 0.61 N/A -3.22 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Prothena Corporation plc and VIVUS Inc.


Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Prothena Corporation plc 0.00% -38.4% -25%
VIVUS Inc. 0.00% 90.4% -11.4%

Risk & Volatility

Prothena Corporation plc is 124.00% more volatile than Standard and Poor’s 500 because the company has a beta of 2.24. From a competition point of view, VIVUS Inc. has a 1.79 beta which is 79.00% more volatile compared to Standard and Poor’s 500.


The current Quick Ratio of Prothena Corporation plc is 27.9 while its Current Ratio is 27.9. Meanwhile, VIVUS Inc. has a Current Ratio of 4 while its Quick Ratio is 3.5. Prothena Corporation plc is better positioned to pay off its short-term and long-term debts than VIVUS Inc.

Insider & Institutional Ownership

Roughly 92.7% of Prothena Corporation plc shares are owned by institutional investors while 17.1% of VIVUS Inc. are owned by institutional investors. 90.1% are Prothena Corporation plc’s share owned by insiders. Comparatively, VIVUS Inc. has 2.1% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Prothena Corporation plc -6.49% -8.86% -7.42% -20.34% -36.28% -9.13%
VIVUS Inc. 1.21% -12.79% -9.73% -29.24% -51.56% 49.78%

For the past year Prothena Corporation plc has -9.13% weaker performance while VIVUS Inc. has 49.78% stronger performance.


Prothena Corporation plc beats VIVUS Inc. on 4 of the 7 factors.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinson’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, the company is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension. It has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. The company also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote STENDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.